Denali Therapeutics Inc. entered into an asset purchase agreement to sell its FDA-awarded Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in cash. The voucher was earned through the approval of AVLAYAHTM (tividenofusp alfa) for Hunter syndrome in March 2026. Denali Therapeutics Inc. is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases.
